EY
EYE.AU Nova EYE Medical Ltd
- Market cap
- AUD 42.7M
- P/E
- -
- P/B
- 2.99x
- ROE
- -30.4%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is EYE.AU undervalued?
Graham numberThe Graham number of Nova EYE Medical Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nova EYE Medical Ltd fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-30.4%), below 10%.
ROA 1/1
Return on assets (-20.1%) is above the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (58.4%) is above the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 27.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (16.8%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (3.0x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Nova EYE Medical Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nova EYE Medical Ltd
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucom…
Full company profileNova EYE Medical Ltd financial statements
Nova EYE Medical Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 71.8M | 79.4M | 16.1M | 12.8M | 13.4M | 13.4M | 17.0M | 23.3M | 29.3M | 34.9M |
| Gross Profit | 41.0M | 46.4M | 13.2M | -1.64M | 1.77M | -765K | 842K | 20.2M | 20.1M | 25.0M |
| Operating Income | -81.0K | -3.53M | -7.05M | -7.18M | -4.97M | -9.88M | -11.8M | -8.97M | -11.2M | -4.38M |
| EBITDA | 1.51M | -1.40M | -4.22M | -5.75M | -3.67M | -7.89M | -14.7M | -5.98M | -8.98M | -2.21M |
| Net Income | -894K | -5.07M | -6.66M | -6.99M | -4.36M | -7.50M | -15.3M | -8.79M | -9.06M | -4.33M |
| EPS | -0.01 | -0.04 | -0.05 | -0.05 | -0.03 | -0.05 | -0.10 | -0.04 | -0.04 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 86.5M | 103M | 99.9M | 117M | 42.0M | 36.6M | 30.4M | 29.9M | 26.5M | 21.6M |
| Total Liabilities | 29.6M | 30.2M | 31.1M | 16.2M | 6.66M | 6.23M | 7.17M | 8.55M | 7.54M | 7.31M |
| Shareholders' Equity | 56.9M | 73.2M | 68.8M | 101M | 35.3M | 30.4M | 23.2M | 21.3M | 19.0M | 14.3M |
| Cash & Short-term Investments | 9.24M | 23.1M | 15.4M | 95.6M | 17.8M | 8.00M | 7.42M | 6.15M | 5.06M | 964K |
| Total Debt | 15.6M | 15.0M | 15.1M | 3.34M | 3.70M | 1.94M | 1.53M | 3.35M | 3.02M | 2.39M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.50M | 522K | -4.21M | 5.45M | -13.1M | -4.68M | -6.72M | -7.86M | -6.15M | -3.12M |
| Capital Expenditure | 7.06M | 2.64M | 726K | 1.66M | 2.23M | 5.59M | 800K | 449K | 426K | 235K |
| Free Cash Flow | -10.6M | -2.12M | -4.93M | 3.79M | -15.4M | -10.3M | -7.52M | -8.31M | -6.58M | -3.36M |
| Ratios | ||||||||||
| ROE | -1.6% | -6.9% | -9.7% | -7.0% | -12.3% | -24.7% | -65.9% | -41.2% | -47.8% | -30.4% |
| ROA | -1.0% | -4.9% | -6.7% | -6.0% | -10.4% | -20.5% | -50.4% | -29.4% | -34.2% | -20.1% |
| Net Profit Margin | -1.2% | -6.4% | -41.3% | -54.7% | -32.5% | -56.0% | -89.8% | -37.7% | -31.0% | -12.4% |
| Debt to Equity | 0.27x | 0.20x | 0.22x | 0.03x | 0.10x | 0.06x | 0.07x | 0.16x | 0.16x | 0.17x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nova EYE Medical Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 21, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | AUD 19.4M | 0.13 | - |
| 2020 | AUD 19.4M | 0.13 | - |
| 2019 | AUD 19.4M | 0.13 | - |
| 2018 | AUD 19.2M | 0.14 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Jul 10, 2001.
Who owns Nova EYE Medical Ltd
- Insiders 18.88%
- Institutions 18.23%
- Public & others 62.89%
- Shares outstanding 285M
- Free float 223M
Nova EYE Medical Ltd company profile
- Company name
- Nova EYE Medical Ltd
- Ticker
- EYE.AU
- ISIN
- AU0000094252
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- June
- Address
- 107 Rundle Street, Kent Town, SA, Australia, 5067
- Phone
- 61 8 8362 0193
- Website
- nova-eye.com
About Nova EYE Medical Ltd
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
Nova EYE Medical Ltd management
2- Mr. Victor PrevinFounder & Chairman · born 1958
- Mr. Thomas H. Spurling AM, BSc (Hons), FRACI, FTSE, Ph.D.MD & Executive Director · born 1962